LNK-01002 is under clinical development by Lynk Pharmaceutical Hangzhou and currently in Phase I for Myelofibrosis. According to GlobalData, Phase I drugs for Myelofibrosis have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LNK-01002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LNK-01002 is under development for the treatment of relapsed and refractory acute myeloid leukemia, primary myelofibrosis, post-essential thrombocythemia myelofibrosis, post-polycythemia vera myelofibrosis and other unspecified indications. It is administered orally as a capsule. The drug candidate is a heterobifunctional PROTAC (proteolysis-targeting chimera) which acts by targeting Ras and cereblon (CRBN).
Lynk Pharmaceutical Hangzhou overview
Lynk Pharmaceutical Hangzhou (Lynk Pharmaceuticals) discovers and develops novel drugs that address the unmet medical needs of various tumors and inflammatory diseases. The company is investigating therapies to treat oncology, immunology and renin–angiotensin system (RAS) disorders. It utilizes Protac technology platform to manufacture its product candidates. Lynk Pharmaceuticals works in partnership with Institute of Oncology and Basic Medicine, Kobe University and the Japan Institute of Physics and Chemistry. The company was funded by Kaitai-Capital, Med-Fine Capital, Sinopharm Capital, Decheng Capital and Zheshang Innovest. Lynk Pharmaceuticals is headquartered in Hangzhou, Zhejiang, China.
For a complete picture of LNK-01002’s drug-specific PTSR and LoA scores, buy the report here.